Site is Being Upgraded

 Life-extension therapy: Fenofibrate, a lipid-lowering medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 13/April/2017, 12.09 am

Neuropeptide-based therapy for blood sugar disease (autoimmune diabetes (TIDM)):  Neuropeptide (NPY), a 36 amino-acid neuropeptide known to play a role in food intake and weight determination,  increases PD-L1 expression,  augments Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 12/April/2018,  11.50 pm
April 12, 2018
Bonding your way to decrease blood pressure/sugar and extend lifespan: Oxytocin-based Lifespan and healthspan extension therapy: Oxytocin,  a peptide hormone and neuropeptide known to play a role in empathy, generosity, child birth and so on, decreases blood sugar and blood pressure levels and prolongs mammalian life span, via down regulation of angiotensin II type I receptor (AT1R), 13/April/2018, 7.09 am
April 13, 2018
Show all

What they say? 

A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ) by Prof Dominic J. Withers, Dr. Selman C and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMDreports, for the first time, that  Life-extension therapy: Fenofibrate, a lipid-lowering medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span


Research findings to Therapeutic opportunity: 

Fenofibrate, by  increasing  the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (fig. 1).   

Figure 1. Mechanistic insight into how Fenofibrate may extend lifespan. Fenofibrate inhibits p70 S6 kInase expression and regulates other genes that promote longevity

Figure 2. The chemical structure of Fenofibrate. Fenofibrate may function as a longevity promoting agent

[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “Fenofibrate   or its analogs,  either alone or in combination with any of the known longevity-promoting compound(s), may be used to extend the lifespan of an individual (fig. 1).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic Information: How  Fenofibrate   decreases the expression of p70 S6 Kinase and promote mammalian life span

# Research cooperation

Amount: $500#

For purchase and payment information, you may reach us at info@genomediscovery.org


References:

CitationBoominathan, L.,   Life-extension therapy: Fenofibrate, a lipid-lowering medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 13/April/2017, 12.09 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.